Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT00424983
- Locations
- 🇺🇸
Oncotherapeutics, West Hollywood, California, United States
🇺🇸Rocky Mountain Cancer Centers RMCC, Greenwood Village, Colorado, United States
🇺🇸Norwalk Hospital, Norwalk, Connecticut, United States
ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer
- Conditions
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2010-02-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 36
- Registration Number
- NCT00415779
- Locations
- 🇮🇹
Istituto Nazionale dei Tumori, Napoli, Italy
🇮🇹Ospedale Oncologico Regionale C.R.O.B. - Basilicata, Rionero in Vulture, Italy
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 1294
- Registration Number
- NCT00412022
- Locations
- 🇮🇹
Istituto Nazionale per la ricerca Sul Cancro, Genova, Italy
🇮🇹Ospedale Santa Chiara, Trento, Italy
🇮🇹Ospedale Unico della Versilia, Lucca, Italy
Maintaining Bone Strength in Men With Prostate Cancer
- Conditions
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 300
- Registration Number
- NCT00391950
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
- Conditions
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 99
- Registration Number
- NCT00391690
- Locations
- 🇩🇪
Novartis Investigative Site, Tuebingen, Germany
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2011-08-23
- Lead Sponsor
- Soroka University Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT00376740
- Locations
- 🇮🇱
Soroka University Medical Center, Beer Sheva, Israel
🇮🇱Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT00375505
- Locations
- 🇩🇪
Novartis Investigative Site, Marburg, Germany
Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT00375648
- Locations
- 🇫🇷
Novartis Investigative Site, Monpellier, France
Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 430
- Registration Number
- NCT00375427
- Locations
- 🇮🇹
Novartis Investigative Site, Forlì, Italy
Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions
- Conditions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00372710
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.